Coralie Reger De Moura (Coralie Reger de Moura)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

Tyrosine Kinase

Metastatic Colorectal Cancer

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Coralie Reger De Moura, Baptiste Louveau, Fanélie Jouenne, Paul Vilquin, Maxime Battistella, Yaelle Bellahsen-Harrar, Aurélie Sadoux, Suzanne Menashi, Nicolas Dumaz, Céleste Lebbé, Samia Mourah
Inactivation of kindlin-3 increases human melanoma aggressiveness through the collagen-activated tyrosine kinase receptor DDR1. Oncogene 43 (21) (2024)
Coralie Reger De Moura, Baptiste Louveau, Fanélie Jouenne, Paul Vilquin, Maxime Battistella, Yaelle Bellahsen-Harrar, Aurélie Sadoux, Suzanne Menashi, Nicolas Dumaz, Céleste Lebbé, Samia Mourah
Inactivation of kindlin-3 increases human melanoma aggressiveness through the collagen-activated tyrosine kinase receptor DDR1. Oncogene 43 (21) (2024)
Coralie Reger De Moura, Baptiste Louveau, Fanélie Jouenne, Paul Vilquin, Maxime Battistella, Yaelle Bellahsen-Harrar, Aurélie Sadoux, Suzanne Menashi, Nicolas Dumaz, Céleste Lebbé, Samia Mourah
Inactivation of kindlin-3 increases human melanoma aggressiveness through the collagen-activated tyrosine kinase receptor DDR1. Oncogene (2024)
Julie Delyon, Anaïs Vallet, Mélanie Bernard-Cacciarella, Isabelle Kuzniak, Coralie Reger De Moura, Baptiste Louveau, Fanélie Jouenne, Samia Mourah, Céleste Lebbé, Nicolas Dumaz
TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro. Cancers 15 (11) (2023)
Alexandra Landras, Coralie Reger De Moura, Bruno O Villoutreix, Maxime Battistella, Aurélie Sadoux, Nicolas Dumaz, Suzanne Menashi, Juan Fernández-Recio, Céleste Lebbé, Samia Mourah
Novel treatment strategy for NRAS-mutated melanoma through a selective inhibitor of CD147/VEGFR-2 interaction. Oncogene 41 (15) (2022)